Abstract |
Forty-five patients with chronic gastric ulcers were treated as out-patients in a double-blind comparison of gefarnate ( geranyl farnesylacetate), 50 mg four times daily, with the same number of dummy capsules daily for five weeks. The mean percentage reduction in ulcer size assessed by radiography was 70-4 per cent in the gefarnate patients compared with 27-8 per cent in those receiving placebo capsules. This difference is statistically significant (p less than 0-05, with a two-tailed test). No change in the electrolyte balance occurred in any of the patients and no side-effects were reported. These results suggest that gefarnate promotes the healing of gastric ulcers in ambulant patients. Its apparent absence of side-effects makes it a safe ans useful drug.
|
Authors | P B Newcomb, W D Stone, P C Richardson, P M Smith, A Gent, B Donovan |
Journal | The Practitioner
(Practitioner)
Vol. 217
Issue 1299
Pg. 435-8
(Sep 1976)
ISSN: 0032-6518 [Print] England |
PMID | 790358
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Fatty Acids, Unsaturated
- Placebos
- Terpenes
|
Topics |
- Clinical Trials as Topic
- Fatty Acids, Unsaturated
(administration & dosage, therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Placebos
- Smoking
- Stomach Ulcer
(drug therapy)
- Terpenes
(administration & dosage, therapeutic use)
|